Analysts think AURA stock price could increase by 169%
Dec 28, 2024, 12:26 PM
-5.28%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
7 analysts think AURA stock price will increase by 169.39%. The current median analyst target is $22.44 compared to a current stock price of $8.33. The lowest analysts target is $21.21 and the highest analyst target is $24.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.